ENZB update: Beryl Capital files 13G/A showing zero stake
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Enzo Biochem (ENZB): Schedule 13G/A filed by Beryl Capital entities shows no current stake. Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin reported 0 shares and 0% beneficial ownership of Enzo Biochem common stock (CUSIP 294100102) as of 09/30/2025.
The filing affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Item 5 indicates ownership of five percent or less of the class. All voting and dispositive powers are listed as 0.
Positive
- None.
Negative
- None.
FAQ
What did Enzo Biochem (ENZB) disclose in this Schedule 13G/A?
A group led by Beryl Capital filed an amended Schedule 13G reporting 0 shares and 0% beneficial ownership of Enzo Biochem common stock.
Who are the reporting persons in the ENZB Schedule 13G/A?
The reporting persons are Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin.
What percentage of Enzo Biochem’s common stock do the filers report?
They report 0% of the class, with 0 shares beneficially owned.
What is the event date referenced in the ENZB filing?
The event date is 09/30/2025.
Does the filing state any intent to influence control of Enzo Biochem?
No. The certification states the securities were not acquired or held to change or influence control.
What are the voting and dispositive powers reported?
Each reporting person lists 0 for sole and shared voting power and 0 for sole and shared dispositive power.
What class and CUSIP are covered in this ENZB filing?
It covers Common Stock, CUSIP 294100102.